President Donald Trump on Sunday announced that a dividend payment of "at least" $2,000 would be paid to most Americans from US tariff revenues. In a post on Truth Social, he wrote: "We are taking in Trillions of Dollars and will soon begin paying down our ENORMOUS DEBT, $37 Trillion.""A dividend of at least $2000 a person (not including high income people!) will be paid to everyone." The Supreme Court is currently reviewing the legality of Trump's sweeping tariffs, which he has justified under the Intern ...

Core Viewpoint - The upcoming Supreme Court hearing on the use of the International Emergency Economic Powers Act (IEEPA) for imposing tariffs is a significant focus for the Trump administration, with potential implications for the medical device industry and broader economic impacts [1][6]. Tariffs and Economic Impact - Trump imposed tariffs under IEEPA in February 2025, with tariffs on China imports currently at 55%, and a potential threat of an additional 100% tariff by November 1 [2]. - The US Treasury Secretary estimates that annual tariff revenue could reach $300 billion in 2025, although experts warn that tariffs negatively affect companies reliant on imports [4]. - The medical device industry is particularly concerned about the impact of tariffs on patient access to essential technologies [3]. Industry Response and Challenges - The Advanced Medical Technology Association (AdvaMed) has urged the Trump administration to consider lower tariffs to promote medtech manufacturing and job growth in the US [3]. - The medical device industry faces significant challenges in shifting manufacturing away from China due to regulatory complexities and the time required for such transitions [7][8]. - Executives in the industry are beginning to develop strategies to navigate the challenges posed by tariffs, including tariff classification and supply chain issues [10][11]. Customs Planning and Strategies - Companies are exploring customs planning strategies to mitigate the impact of tariffs, including utilizing the first sale rule for customs duties [13][15]. - New middleman structures are being created to separate intellectual property from manufacturing costs, allowing companies to potentially reduce customs duties [16][17]. Legislative Context - The ongoing US-China trade war complicates the situation, with China implementing additional export controls on rare earth metals critical for medical device production [17]. - Congress has not passed a miscellaneous tariff bill since Biden took office, which previously provided temporary duty suspensions for essential imports [19][20]. - There is a call for Congress to take action to alleviate tariff pressures on the medical device industry, as the current situation remains unresolved [20].